Tonix Pharma (TNXP) has released an update.
Tonix Pharmaceuticals Holding Corp. shareholders gave the green light to two key proposals during their Special Meeting on February 15, 2024. The first proposal passed, allowing the issuance of over 162 million new shares upon exercise of Series C and D warrants, a move aligned with Nasdaq’s listing requirements. The second proposal approved a contingency plan to adjourn the meeting to gather more votes if necessary. This decisive turnout reflects shareholder support for the company’s strategic financing moves and ensures compliance with the stock market’s regulations.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
